Background: CSL is one of Australia's biggest biotech success stories, originally founded in Melbourne out of CSIRO labs. Today, it operates a global healthcare empire across plasma therapies through CSL Behring, flu vaccines through Seqirus, and iron deficiency treatments through CSL Vifor.

What happened: CSL has cut its earnings guidance just three months after reaffirming it, warning that both revenue and profit will come in lower than expected. The company also flagged a massive $5 billion USD impairment on its Vifor division - the iron deficiency business it bought in 2022 for $11.7 billion USD.  

What else: The market reaction was brutal. CSL shares plunged 18% after the announcement, wiping billions from the company's market value. The Vifor write-down effectively means almost half the acquisition's value has disappeared in just four years, with some analysts describing the result as a "kitchen-sink downgrade."  

What's the key learning?

💡 Sometimes the best time to dump bad news is when you're already having a terrible day. Companies will often bundle every write-down, missed target and weak forecast into one painful announcement to reset expectations all at once.

💡 New CEOs often use this strategy to "clear the decks" and create a recovery story. At Tabcorp, CEO Gil McLachlan unveiled a $1.4 billion loss and major write-downs shortly after arriving in 2024, while ANZ's Nuno Matos launched a "permanent transformation" involving restructuring and job cuts after taking over in 2025. In both cases, the idea was to lower expectations early so that future improvements would look stronger.

💡 The gamble only works if investors believe the worst is finally over. Both Tabcorp and ANZ have seen their share prices recover more than 10% from their lows after resetting expectations - but CSL's sharp sell-off shows many investors still aren't convinced the company has finished taking the pain.